Claims for Patent: 10,010,530
✉ Email this page to a colleague
Summary for Patent: 10,010,530
Title: | Carboxamide derivative and its diastereomers in stable crystalline form |
Abstract: | The present disclosure relates to solid crystalline forms of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-- hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament. ##STR00001## |
Inventor(s): | Tormakangas; Olli (Turku, FI), Heikkinen; Terhi (Lieto, FI) |
Assignee: | Orlon Corporation (Espoo, FI) |
Application Number: | 15/547,193 |
Patent Claims: |
1. Crystalline form I of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having an X-ray powder
diffraction pattern comprising characteristic peaks at about 8.5, 10.4, 16.6, 16.9, and 24.3 degrees 2-theta.
2. Crystalline form I' of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia) having an X-ray powder diffraction pattern comprising characteristic peaks at about 9.3, 15.7, 17.0, 24.1 and 25.1 degrees 2-theta. 3. Crystalline form I'' of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((R)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ib) having an X-ray powder diffraction pattern comprising characteristic peaks at about 9.2, 10.9, 15.1, 15.8 and 22.1 degrees 2-theta. 4. A process for preparing crystalline form I, I' or I'' of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I), N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia) or N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((R)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ib), respectively, comprising a) mixing N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I), N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia) or N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((R)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ib) with a mixture of acetonitrile and water; b) heating the mixture from step a) to form a solution; c) cooling the solution from step b) to about 0-50.degree. C.; and d) isolating the crystalline form. 5. The process according to claim 4, wherein the acetonitrile:water mixture has a volume ratio from about 85:15 to about 99:1. 6. The process according to claim 5, wherein the acetonitrile:water mixture has a volume ratio from about 90:10 to about 98:2. 7. The process according to claim 6, wherein the acetonitrile:water mixture has a volume ratio of about 95:5. 8. The process according to claim 4, wherein the cooling step c) occurs over about 5 to about 24 hours. 9. The process according to claim 8, wherein the cooling step c) occurs over about 6 to about 12 hours. 10. The process according to claim 4, wherein the isolated crystalline form is dried under vacuum at about 40.degree. C. to about 60.degree. C. 11. The crystalline form I of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) of claim 1, further having an X-ray powder diffraction pattern comprising characteristic peaks at about 9.7, 15.9, 19.2, 21.8 and 25.5 degrees 2-theta. 12. The crystalline form I' of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((S)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ia) of claim 2, further having an X-ray powder diffraction pattern comprising characteristic peaks at about 11.4, 14.9, 17.7, 20.5 and 27.2 degrees 2-theta. 13. The crystalline form I'' of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((R)- -1-hydroxyethyl)-1H-pyrazole-3-carboxamide (Ib) of claim 3, further having an X-ray powder diffraction pattern comprising characteristic peaks at about 7.9, 16.9, 18.4, 20.2 and 21.8 degrees 2-theta. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.